{"id":"https://openalex.org/W1966789767","doi":"https://doi.org/10.1158/1538-7445.am2012-2797","title":"Abstract 2797: AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models","display_name":"Abstract 2797: AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models","publication_year":2012,"publication_date":"2012-04-01","ids":{"openalex":"https://openalex.org/W1966789767","doi":"https://doi.org/10.1158/1538-7445.am2012-2797","mag":"1966789767"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2012-2797","doi":"https://doi.org/10.1158/1538-7445.am2012-2797","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2012-2797","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Nancy Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nancy Zhang","raw_affiliation_strings":["1Amgen Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Amgen Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108833346","display_name":"Sean R. Caenepeel","orcid":"https://orcid.org/0000-0002-9446-4927","observed_orcids":["https://orcid.org/0000-0002-9446-4927"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sean Caenepeel","raw_affiliation_strings":["1Amgen Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Amgen Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100418073","display_name":"Ling Wang","orcid":"https://orcid.org/0000-0003-3220-6065","observed_orcids":["https://orcid.org/0000-0003-3220-6065"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ling Wang","raw_affiliation_strings":["1Amgen Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Amgen Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049963981","display_name":"Mark H. Norman","orcid":"https://orcid.org/0009-0002-4399-5493","observed_orcids":["https://orcid.org/0009-0002-4399-5493"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Norman","raw_affiliation_strings":["1Amgen Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Amgen Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110966809","display_name":"Richard L. Kendall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Kendall","raw_affiliation_strings":["1Amgen Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Amgen Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004222879","display_name":"Terri Burgess","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Terri Burgess","raw_affiliation_strings":["1Amgen Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Amgen Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078787495","display_name":"Robert Radinsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Radinsky","raw_affiliation_strings":["1Amgen Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Amgen Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102816712","display_name":"Paul E. Hughes","orcid":"https://orcid.org/0000-0003-1095-9883","observed_orcids":["https://orcid.org/0000-0003-1095-9883"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Hughes","raw_affiliation_strings":["1Amgen Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Amgen Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112250130","display_name":"Daniel J. Freeman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel J. Freeman","raw_affiliation_strings":["1Amgen Inc., Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Amgen Inc., Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1320553840"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"72","issue":"8_Supplement","first_page":"2797","last_page":"2797"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11339","display_name":"Metabolism, Diabetes, and Cancer","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pi3k-signaling","display_name":"PI3K signaling","score":0.7860000133514404},{"id":"https://openalex.org/keywords/akt-phosphorylation","display_name":"Akt phosphorylation","score":0.9300000071525574},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9279999732971191},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9980000257492065},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.8109999895095825},{"id":"https://openalex.org/keywords/kras-mutant-colorectal-cancer","display_name":"KRAS-mutant colorectal cancer","score":0.7480000257492065},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.8410000205039978},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.5519999861717224},{"id":"https://openalex.org/keywords/cell-proliferation","display_name":"cell proliferation","score":0.6259999871253967},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.515999972820282},{"id":"https://openalex.org/keywords/antitumor-efficacy","display_name":"antitumor efficacy","score":0.6380000114440918},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.38499999046325684},{"id":"https://openalex.org/keywords/drug-repurposing","display_name":"drug repurposing","score":0.3100000023841858}],"concepts":[{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.7703836560249329},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.6348544359207153},{"id":"https://openalex.org/C2777609662","wikidata":"https://www.wikidata.org/wiki/Q416356","display_name":"PTEN","level":4,"score":0.5751415491104126},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5099915266036987},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.5029928088188171},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.4846513867378235},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4739648997783661},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.47296375036239624},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.46252498030662537},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4361564517021179},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43604832887649536},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.38395506143569946},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.15985727310180664},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.15487349033355713},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08162906765937805},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2012-2797","doi":"https://doi.org/10.1158/1538-7445.am2012-2797","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2012-2797","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2028914732","https://openalex.org/W2044484262","https://openalex.org/W2015598798","https://openalex.org/W2038141559","https://openalex.org/W2115484306","https://openalex.org/W1436721071","https://openalex.org/W2272173799","https://openalex.org/W2336761881","https://openalex.org/W1963537855","https://openalex.org/W2093809146"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Constitutive":[2],"activation":[3],"of":[4,46,63,82,138,169,171,191,197,210,223,270,304,371,385,395,409,430,435],"the":[5,37,40,70,76,369,405,419,431,436],"phosphoinositide":[6],"3-kinases":[7],"(PI3K)":[8],"signaling":[9],"pathway":[10,288,363],"is":[11,28,345,368],"a":[12,49,136,189,227,301,346,378],"frequent":[13],"event":[14],"in":[15,20,60,69,141,149,212,243,281,300,307,337,355,374,380,412,418],"many":[16],"cancers":[17],"and":[18,24,43,51,57,79,121,164,184,193,236,249,309,316,388,392],"results":[19],"increased":[21,220],"cell":[22,180,330,387,390,397],"growth":[23,272,366],"survival.":[25],"Therefore,":[26],"PI3K":[27,55,71,287,362,381,420],"an":[29,131,372,383,393],"attractive":[30],"target":[31],"for":[32,404,439],"oncology.":[33],"This":[34],"study":[35],"evaluated":[36],"correlation":[38],"between":[39],"pharmacokinetics":[41],"(PK)":[42],"pharmacodynamics":[44],"(PD)":[45],"AMG":[47,83,110,139,172,206,224,239,257,276,296,325,343,375,410],"511,":[48,84],"potent":[50,347],"selective":[52],"class":[53],"I":[54],"inhibitor,":[56,349],"anti-tumor":[58,353],"activity":[59,354],"preclinical":[61],"models":[62,285,359],"human":[64,356],"cancer":[65],"which":[66,350,360],"harbor":[67,361,416],"mutations":[68,289,417],"pathway.":[72,421],"Method:":[73],"To":[74,147],"determine":[75,148],"PD,":[77],"PK,":[78],"efficacy":[80],"relationship":[81],"U87":[85,142,155,199,213,338],"MG":[86,143,200,214,339],"(PTEN":[87],"null),":[88],"HCT-116":[89],"(PI3K":[90,96],"&":[91],"KRAS":[92],"mutant),":[93],"or":[94,158],"BT474":[95,159],"mutant,":[97],"HER2":[98],"amplified)":[99],"tumor":[100,117,144,215,244,283,308,329,340,357,386,396],"bearing":[101,145,153],"mice":[102,152],"were":[103,161],"treated":[104,162],"with":[105,205,219,233,254,275,286],"up":[106,262],"to":[107,263],"10":[108,255],"mpk":[109,238,256],"511":[111,140,173,225,240,258,277,297,326,344,376,411],"daily":[112,163],"by":[113,176,246,334],"oral":[114],"gavage.":[115],"For":[116],"PD":[118],"time":[119],"course":[120],"dose":[122,229],"response":[123],"studies,":[124],"AKT":[125],"phosphorylation":[126],"(pAKT)":[127],"was":[128,174,217,273],"measured":[129,165,333],"using":[130,188],"electrochemiluminescence":[132],"detection":[133],"assay":[134],"after":[135,226],"single-dose":[137],"mice.":[146],"vivo":[150],"efficacy,":[151],"established":[154],"MG,":[156],"HCT-116,":[157],"tumors":[160,202,415],"2x/week.":[166],"The":[167],"mechanism":[168],"action":[170],"determined":[175],"examining":[177],"effects":[178],"on":[179],"proliferation":[181,391],"(BrdU":[182],"incorporation)":[183],"apoptosis":[185,331],"(caspase":[186],"staining)":[187],"combination":[190],"immunohistochemistry":[192],"flow":[194],"cytometry":[195,292],"analyses":[196],"ex-vivo":[198],"xenograft":[201,271,284,358],"following":[203],"treatment":[204,298,327],"511.":[207],"Results:":[208],"Inhibition":[209],"pAKT":[211,242,261],"tissue":[216,245],"associated":[218],"plasma":[221,318],"concentration":[222],"single":[228],"(EC50=59":[230],"ng/mL).":[231],"Treatment":[232,253],"0.3,":[234],"1,":[235],"3":[237],"inhibited":[241,260],"39,":[247],"81,":[248],"92":[250],"%,":[251],"respectively.":[252],"significantly":[259],"16":[264],"hrs":[265],"(p<0.01).":[266],"A":[267],"dose-dependent":[268,302],"inhibition":[269,367,384],"observed":[274],"versus":[278],"vehicle":[279],"control":[280],"multiple":[282],"(p<0.03).":[290],"Flow":[291],"analysis":[293,322],"demonstrated":[294],"that":[295,324],"resulted":[299],"decrease":[303],"BrdU":[305],"incorporation":[306],"CD31":[310],"positive":[311],"endothelial":[312,389],"cells":[313],"at":[314],"peak":[315],"trough":[317],"levels":[319],"(p<0.05).":[320],"Immunohistochemical":[321],"confirmed":[323],"induced":[328],"as":[332],"caspase":[335],"staining":[336],"samples.":[341],"Conclusion:":[342],"pan-PI3K":[348],"has":[351],"significant":[352],"mutations.":[364],"Tumor":[365],"result":[370],"increase":[373],"exposure,":[377],"reduction":[379],"signaling,":[382],"induction":[394],"apoptosis.":[398],"These":[399],"data":[400],"together":[401],"provide":[402],"evidence":[403],"potential":[406],"clinical":[407],"investigation":[408],"patients":[413],"whose":[414],"Citation":[422],"Format:":[423],"{Authors}.":[424],"{Abstract":[425],"title}":[426],"[abstract].":[427],"In:":[428],"Proceedings":[429],"103rd":[432],"Annual":[433],"Meeting":[434],"American":[437],"Association":[438],"Cancer":[440,451],"Research;":[441],"2012":[442],"Mar":[443],"31-Apr":[444],"4;":[445],"Chicago,":[446],"IL.":[447],"Philadelphia":[448],"(PA):":[449],"AACR;":[450],"Res":[452],"2012;72(8":[453],"Suppl):Abstract":[454],"nr":[455],"2797.":[456],"doi:1538-7445.AM2012-2797":[457]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}